29Jan 2023
Phase II proof‐of‐concept study of atorvastatin in castration‐resistant prostate cancer

Phase II proof‐of‐concept study of atorvastatin in castration‐resistant prostate cancer

The SPECTRE trial tested for evidence of statin‐mediated effects in patients with castration‐resistant prostate cancer (CRPC) as post‐diagnosis use of statins in patients with prostate cancer is associated with favourable survival outcomes. One of 12 patients experienced a ≥50% drop in PSA levels, with ≥2 patients satisfying the primary endpoint required for further recruitment. All 12 patients experienced substantial falls in serum cholesterol levels following statin treatment. While all patients had comparable pre‐study PSA velocities, six of 12 patients showed decreased PSA velocities after statin treatment, suggestive of disease stabilization. Data from the SPECTRE study provided the first evidence of statin‐mediated effects on CRPC and early signs of disease stabilization. The data also highlight the possibility of altered tryptophan metabolism associated with tumour response.

  • #urology

Like

Save

Share